Dear Friends and Supporters of Us TOO,
University of Iowa researchers are
conducting Phase 2 research studies of a vaccine to treat men with recurrent
prostate cancer. The
studies are enrolling two patient populations into
separate treatment protocols.
Protocol #1
Men with the first
evidence of recurrent disease following initial treatment as determined by a
continued rise in PSA levels
Protocol #2
Men with castrate-resistant
prostate cancer who have been treated by hormone therapy and continue to
progress with or without evidence of the spread of the cancer.
Each
person will be screened for eligibility to enter the study and, if accepted,
will receive three vaccinations, each 30 days apart, followed by regular
visits to the University of Iowa Hospitals and Clinics to follow their
immune status, clinical laboratory analyses, and status of their recurrent
disease.
Details can be found at
http://www.ustooevents.org/site/R?i=UPJKu_MI2YsMlFr2A0KTyw
-- trials NCT00583752 and NCT00583024.
Interested men should contact
the Clinical Trial Coordinator, Ms. Pamela Zehr, RN, MA at 319-353-8914; pamela-zehr@uiowa.edu
Please feel
free to forward this message along to other patients or caregivers you know
who are dealing with prostate cancer, or to
physicians who might be
interested in sharing the information with their patients. Thank you in
advance for your consideration and
participation.
Sincerely,
Thomas Kirk
President & CEO
Us
TOO International
Downers Grove, IL 60655
Office: 630-795-1002
Toll
Free: 800-808-7866
tom@ustoo.org
